Traders should monitor NMPA approval decisions for sovleplenib in both wAIHA and ITP, priority review timelines typically 6 months, so decisions could come by late 2026 / early 2027. Positive outcomes would be major catalysts for HCM as a pure-play owner of a first-in-class Syk inhibitor. Near-term, watch for potential partnership or ex-China licensing deals given HUTCHMED retains global rights.
HCM drugs
HCM drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $10.83entry
- T+1 · 5mo ago −3.14%α −2.54% · $10.49
- T+5 · 5mo ago −6.19%α −3.37% · $10.16
- T+20 · 4mo ago +7.02%α +7.02% · $11.59
- T+60 · 2mo ago +21.14%α +20.75% · $13.12
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED announced positive Phase 3 results for sovleplenib in warm AIHA (wAIHA), showing a 66% durable response rate vs 15% for placebo (p<0.0001). The NDA for wAIHA has been accepted and granted priority review by China's NMPA, and a separate resubmitted NDA for ITP also received priority review. These developments significantly strengthen sovleplenib's regulatory and commercial prospects in two indications with high unmet need.
Key Facts
- Phase 3 ESLIM-02 study met primary endpoint: durable response rate 66% for sovleplenib vs 15% for placebo (p<0.0001) in wAIHA patients.
- Overall response rate (Hb ≥100 g/L + ≥20 g/L increase without rescue) was 70% vs 22% (p<0.0001).
- Rescue therapy use reduced to 16% (sovleplenib) vs 54% (placebo); RBC transfusions reduced to 11% vs 43%.
- Median time to response was 3.1 weeks for sovleplenib vs 6.3 weeks for placebo.
- FDA-like NDA for wAIHA accepted and granted priority review by NMPA in April 2026; Breakthrough Therapy Designation granted March 2026.
- Resubmitted NDA for ITP accepted and granted priority review by NMPA in February 2026.
- Favorable safety profile: Grade ≥3 TEAEs in 43% (sovleplenib) vs 59% (placebo); no TEAE-related deaths or discontinuations in sovleplenib arm.
- HUTCHMED retains all worldwide rights to sovleplenib.
Financial Impact
Sovleplenib targets two sizable markets: wAIHA (significant unmet need in China with no approved targeted therapy) and ITP (430K existing patients, 41K new/year in China). Regulatory approval in either indication could generate substantial revenue; no financial projections provided.
Risk Factors
- Regulatory risk: NMPA may still reject or request additional data before approval.
- Commercial risk: WAIHA and ITP markets require physician education and pricing/reimbursement negotiations.
- Competition: Existing therapies (steroids, TPO-RAs, rituximab) remain available; sovleplenib must demonstrate clear cost-benefit advantage.
- China regulatory environment: drug pricing control and reimbursement policy could limit peak revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310859 |
Track record
33 reports on HCM
7 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 17 of 22 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers